

CHANGE OF REGISTERED OFFICE ADDRESS AND PRINCIPAL PLACE OF BUSINESS

Perth, Australia, 10 December 2019: Australian medical technology company BARD1 Life Sciences Limited (ASX:BD1) (**BARD1** or the **Company**), advises that in accordance with ASX Listing Rule 3.14 and with immediate effect, its registered office and principal place of business will be:

Unit 202, Level 2
39 Mends Street
South Perth WA 6151

BARD1's telephone, facsimile and post office box numbers remain unchanged.

P Collinson
Company Secretary

ABOUT BARD1 LIFE SCIENCES LTD

BARD1 Life Sciences Ltd (ASX:BD1) is an Australian medical technology company focused on developing and commercialising non-invasive diagnostic tests for early detection of cancer. BARD1 owns a proprietary tumour marker platform with potential diagnostic and therapeutic applications across multiple cancers. The pipeline includes BARD1 autoantibody tests in development for early detection of breast, ovarian and lung cancers. BARD1's vision is to detect cancer early and save lives. For more information on BARD1, see www.bard1.com.